

Merck assumes 2023 to be challenging with negative foreign exchange effects

09 March 2023 | News

Growth of life science business sector is subject to higher volatility in 2023



Merck, a leading science and technology company, delivered profitable growth despite challenges in fiscal 2022. Group net sales increased by 12.9% (organically: 6.4%) to \in 22,232 million compared with the previous year. Sales growth was driven by all regions and business sectors, particularly Life Science.

The Big 3 businesses – Process Solutions and Life Science Services, new Healthcare products as well as Semiconductor Solutions – accounted for almost 90% of the organic growth in sales.

But Merck assumes that 2023 will be a challenging year. Based on current assumptions, Merck expects negative foreign exchange effects of about -1% to -4% to weigh on both net sales and EBITDA pre.

The growth of its life science business sector is subject to higher volatility due to the varying developments across product groups and customer segments. Increased research and development activity as well as higher production volumes among pharmaceutical companies, especially in the biopharmaceutical segment, are the key drivers of growth in the key business.